We report favorable survival, local control and adverse event rates following high dose IG-IMRT. Further follow-up is needed to confirm long-term efficacy.

No abstract

The combination of palladium complex (tBu3P)Pd(Me)Cl (1) and NaB[3,5‐(CF3)2C6H3]4 (NaBAr4) catalyzed homopolymerization of a novel monomer, norbornene (NB) with a pendent 2‐fluorosulfonyltetrafluoroethoxymethyl chain (NBSF). Catalytic activities of 1/NaBAr4 were higher than those of previously reported palladium or nickel catalysts, probably, because the palladium center with electron donative tBu3P ligand was barely poisoned by the sulfonyl fluoride coordination. Thus, 1/NaBAr4 is the current best catalyst system for NBSF polymerization. The catalyst system also gave copolymers of NB with NBSF. The obtained copolymers have high sulfonyl‐fluoride incorporation and a narrow molecular weight distribution. Present catalyst system could control incorporation ratio of NBSF by changing a feed monomer ratio with slow addition of NB solution. © 2008 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 46: 5133–5141, 2008

No abstract

Interstitial BRT with or without EBRT appears to result in satisfactory outcome in children with STS. Radical BRT alone, when used judiciously in select groups of children, results in excellent local control and functional outcome with reduced treatment-related morbidity.

This single institutional study evaluated the prognostic factors and treatment outcome of 113 Indian patients with primary nasopharyngeal non-Hodgkin's lymphoma. At presentation, 28% had stage I and 62% had stage II disease. Treatment comprised of a combination of chemotherapy (CTh) and radiotherapy (RT) in the majority of the patients (76%). After a median follow-up of 56 months, the 5-year disease-free survival (DFS) and overall survival (OS) for the whole group were 55.8% and 57.9%, respectively. Multivariate analysis showed that; age > 30 years [hazard ratio (HR) = 6.59, 95% confidence interval (CI) = 2.59 - 16.7, P < 0.0001], WHO performance score > or = 2 (HR = 2.34, 95% CI = 1.01 - 5.46, P = 0.050), T-cell lymphomas (HR = 2.81, 95% CI = 1.14 - 6.96, P < 0.001) and the presence of B symptoms (HR = 3.65, 95% CI = 1.77 - 7.53, P = 0.025), had a negative influence on survival. Patients treated with a combination of CTh and RT had a significantly better outcome than those treated with CTh alone (OS: 69%vs. 31%, P < 0.00001). HR for death in the CTh alone group was 3.73 (95% CI = 1.95 - 7.13). The CR (P = 0.01), DFS (P = 0.01) and OS (P = 0.03) rates were significantly better for patients receiving a RT dose of > or =4500 cGy. HR in the subgroup that received a RT dose of <4500 cGy was 2.51 (95% CI = 1.04 - 6.06). These results suggest that combined modality treatment, comprising of CTh and RT (with an RT dose of > or =4500 cGy), results in satisfactory outcome in patients with this rare neoplasm.

Temporary perioperative iridium-192 interstitial BRT with or without EBRT after function-preserving surgery results in satisfactory outcome in patients with STS. Both low dose rate and high dose rate BRT are equivalent in terms of disease control and complications when used alone or in combination with EBRT. BRT results in fewer complications compared with the combination of BRT and EBRT.

No abstract